p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance-Reference-Cited by-同舟云学术

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance

Published:2023-04 Issue:4 Volume:36 Page:100100
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Modern Pathology

Author:

Mueller Sophie,Grote Isabel,Bartels Stephan,Kandt Leonie,Christgen Henriette,Lehmann Ulrich,Gluz Oleg,Graeser Monika,Kates Ron,Harbeck Nadia,Kreipe Hans,Christgen Matthias^ORCID

Funder

Deutsche Krebshilfe

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference45 articles.

1. Comprehensive molecular portraits of human breast tumours;Koboldt;Nature,2012

2. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer;Olivier;Clin Cancer Res,2006

3. Distinct tumor protein p53 mutants in breast cancer subgroups;Dumay;Int J Cancer,2013

4. Whole-genome analysis informs breast cancer response to aromatase inhibition;Ellis;Nature,2012

5. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer;Grote;Cancer Med,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations;Virchows Archiv;2024-08-27

2. TP53-associated early breast cancer: new observations from a large cohort;JNCI: Journal of the National Cancer Institute;2024-04-03

3. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes;Human Pathology;2024-04

4. Genetic and clinical landscape of ER + /PR- breast cancer in China;BMC Cancer;2023-12-04

5. Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences;2023-11-13